SBRI HEALTHCARE: Competition 26 – Stroke

The SBRI (Small Business Research Initiative) Healthcare Programme is committed to supporting the NHS in delivering the objectives of the NHS Long Term Plan (LTP). Phase 3 funding supports implementation studies that generate the evidence in real-world settings necessary to progress towards future uptake and provide potential adopting organisations with an understanding of the implementation pathway and assurance of benefit delivery. 

Deadline: 18 September 2024 1:00pm BST 

life science & health sector

Dates

Competition closes: 18 September 2024 1:00pm BST 

Application open: 31 July 2024  

Selection Panel: December 2024 

Contracts start: January – February 2025  

 

Scope 

This SBRI Healthcare competition is funded by the AAC in partnership with the Health Innovation Network to facilitate the collection of evidence in real-world settings and build on the value proposition of mature products for adoption and spread. The projects will be selected primarily on their potential value to the health service and social care system, and on the improved outcomes delivered for those in receipt of care. 

Specific Themes 

In 2024/25, SBRI Healthcare Phase 3 seeks to address challenges in Stroke and aims to identify solutions at an advanced stage of development: 1. Early diagnosis 2. Rehabilitation 3. Life after stroke. 

Projects that will not be funded 

  • Basic research and innovations in the creation phase.
  • Systems and solutions that will not easily integrate or communicate with NHS/community setting systems. Some evidence of interoperability and/or work to assess this will be required.
  • Technologies that do not comply with GDPR policies. 
  • Technologies that may increase burden on the workforce. 
  • Wellness or wellbeing digital applications on healthy diet and/or physical exercising.
  • Technologies that will exacerbate health inequalities (including digital exclusion or data inequalities) and inequity of access to care e.g., digital technologies that are inaccessible to certain communities that experience digital poverty. 
  • Innovations that are not co-designed with patients and end users.

 

Eligibility  

  • UKCA marked.
  • If CE-marked only, a clear timeline to achieve UKCA mark by June 2028 for general medical devices or June 2030 for in vitro diagnostic medical devices. If regulatory approval is yet not obtained, evidence should be provided to demonstrate that the innovation is close to obtaining approval and/or in use in at least one NHS Hospital Trust.
  • Clinical efficacy and safety demonstrated through an appropriate and relevant clinical evaluation.
  • All projects must demonstrate relevant partnerships with a clinical partner and service(s)/clinical sites lined up.
  • Projects are strongly encouraged to conduct an independent evaluation.
  • For digital solutions, evidence that the technology has passed or is close to passing the necessary information governance and cyber security requirements where relevant. Evidence that the NHS England Digital Technology Assessment Criteria (DTAC) has been considered.

 

Funding Rates 

The Phase 3 funding – one phase only and is intended to facilitate the implementation of developed innovations. Contracts will be for a maximum of 12 months and up to £500,000 (NET) per project. The implementation will be 100% funded and suppliers for each project will be selected by an open competition process and retain the intellectual property rights (IPR) generated from the project, with certain rights of use retained by the NHS. 

 

How PNO can support you 

The UK team has a strong track record in securing some of the most competitive national and European grants on behalf of its clients, with a full understanding of how a project should be presented to stand the highest chance of success. Each year in the UK alone, we are responsible for the submission of more than 100 funding applications across all sectors and priority areas. Based on this extensive experience, through careful project selection and using key insight into how a project should be best positioned, we consistently achieve success rates that are more than 5 times the typical success rates for UK national schemes and EU programmes. 

Contact us for further information







     privacy statement is applicable